NEW YORK (GenomeWeb News) - Elan Pharmaceuticals has joined the MetaTox Consortium, a group spearheaded by informatics firm GeneGo that aims to address the reasons behind the failure of investigational drugs in clinical trials.
 
GeneGo said the consortium includes members from industry and the US Food and Drug Administration and will focus on using systems biology tools and informatics to assess the safety of small molecule compounds and therapeutics.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.